Substituted Piperidine Compounds for Selective Orexin Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various disorders mediated by orexin receptor activity, such as sleep-wake cycle disorders, neurological disorders, and metabolic issues, lack effective modulators that can selectively target orexin-1 and orexin-2 receptors to achieve therapeutic benefits without significant side effects.
Innovation Solution
Development of substituted piperidine compounds that act as selective modulators of orexin receptors, specifically designed to target orexin-1 and orexin-2 receptors, which can be used in pharmaceutical compositions to treat a wide range of disorders including sleep disorders, neurological conditions, and metabolic issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders mediated by orexin receptor activity, then therapeutic benefits are limited, but side effects are significant due to lack of selective targeting
Solution Approach 1:
The invention divides the orexin receptor system into two distinct targets: orexin-1 receptor and orexin-2 receptor. By developing compounds that can selectively modulate each receptor type independently, the patent enables precise therapeutic intervention. The substituted piperidine compounds are designed to target specific receptor subtypes, allowing clinicians to choose orexin-1 selective modulators for appetite regulation and orexin-2 selective modulators for sleep-wake cycle disorders, thereby achieving therapeutic benefits while minimizing off-target side effects.
2Adaptability or versatility
If non-selective modulators are used to target orexin receptors, then broad therapeutic coverage is achieved, but selectivity between orexin-1 and orexin-2 receptors is lost
Solution Approach 1:
The patent applies local quality by designing substituted piperidine compounds with specific molecular characteristics that enable selective binding to either orexin-1 or orexin-2 receptors. By modifying the piperidine core structure with specific substituents at defined positions, the invention creates compounds with tailored selectivity profiles. This allows each compound to have optimized affinity for a particular receptor subtype, achieving both therapeutic coverage and receptor selectivity simultaneously.
Solution Approach 2:
The invention utilizes parameter changes by systematically varying the substituent groups on the piperidine core structure. By changing the chemical parameters of the substituents (such as their size, polarity, and electronic properties), the patent tunes the compound's selectivity between orexin-1 and orexin-2 receptors. This structure-activity relationship approach enables the development of a series of compounds with different selectivity profiles, allowing optimization for specific therapeutic indications.
3Object-affected harmful factors
If selective orexin receptor modulators are developed, then side effects are reduced, but drug development complexity increases
Solution Approach 1:
The patent employs universality by developing a single substituted piperidine core structure that can serve multiple therapeutic functions. By modifying this universal core with different substituents, the invention generates a family of compounds that can target either orexin-1 or orexin-2 receptors, or even act as dual modulators. This multi-functional platform approach reduces overall development complexity compared to creating separate drug programs for each receptor subtype, as the core synthesis and optimization strategies can be reused across the compound series.
Data Source
Figure 1
AI summary
The present invention is directed to compounds of Formula I: wherein X is CR1 or N; Y is CR2 or N; Z is NH or O; R1 is alkoxy, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrimidinyl; R2 is H, alkyl, or halo; R3 is H, alkyl, alkoxy, halo, triazolyl, oxazolyl, or pyrimidinyl; R4 is alkyl; R5 is pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl; wherein the pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl is optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, or phenyl; and R6 is H or alkyl. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.